Skip to content

European Stocks Mixed: Siemens Energy Surges, Roche & Redcare Face Challenges

Siemens Energy's impressive gains may not last. Roche's weight loss drug could face setbacks, and Redcare Pharmacy's falling active users raise concerns.

There is a pharmacy store and there is a vehicle in front of it and there is a building in the left...
There is a pharmacy store and there is a vehicle in front of it and there is a building in the left corner.

European Stocks Mixed: Siemens Energy Surges, Roche & Redcare Face Challenges

European stock markets have seen mixed fortunes for Roche, Siemens Energy, and CVS Pharmacy. While Siemens Energy has surged over 100 percent this year, analysts advise caution due to limited upside. Roche's stock faces potential challenges with its weight loss medication, and CVS Pharmacy's shares may be worth selling due to declining active users.

Siemens Energy has been a standout performer, gaining over 100 percent since the start of the year. However, experts suggest it has little room to rise further, with an average upside of just two percent. The increased likelihood of a second American presidency for Trump has put pressure on green tech stocks like Siemens Energy.

Roche, a Swiss pharmaceutical company, faces uncertainty about the tolerability of its weight loss medication CT-996. JPMorgan has rated Roche's stock as 'Underweight' due to these concerns. Despite promising results, CT-996 may face setbacks in future studies. Roche's stock offers the most opportunities and risks among the three mentioned European stocks.

CVS Pharmacy's app downloads have remained steady but lack a clear impetus. Jefferies has given the stock a 'Buy' rating, but the number of active users has declined for three consecutive months. This weak recent price performance may warrant selling the stock, according to some analysts.

Investors should exercise caution when considering Siemens Energy, Roche, and CVS Pharmacy stocks. While Siemens Energy has seen significant gains, its upside potential is limited. Roche faces uncertainty with its weight loss medication, and CVS Pharmacy's declining active users may impact its stock performance. Analysts advise selling CVS Pharmacy stock due to lack of clear market leadership among German online pharmacies.

Read also:

Latest